Stand-Alone PDP Options Continue to Dwindle for 2024, While Premiums Rise

The stand-alone Prescription Drug Plan (PDP) market — which was already in decline — is poised to take even more hits due to regulatory and legislative changes that are taking effect in 2024 and beyond, according to industry observers. Indeed, one expert who analyzed data from CMS’s 2024 Medicare Advantage and Part D “landscape files” predicts that “a lot of people are faced with pretty significant premium increases” next year.

There’s a complicated calculus driving that trend, explains Tom Kornfield, a senior consultant at Avalere Health. But both he and equities analyst George Hill agree that the Inflation Reduction Act of 2022 (IRA) is a major factor.

© 2024 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

document-with-the-title-medicare-part-d
October 12

Enrollees Will Face Fewer Medicare PDP Options, Higher Average Premiums in 2024

READ MORE
pills-and-money
August 3

IRA Changes Will Drive Up Part D Bid in 2024, But Premiums Will Stabilize

READ MORE
medicare-enrollment-form
October 5

2024 MA Landscape: MAOs Pursue ‘Softer’ Expansions, Higher Premiums Over Benefit Cuts

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today